GlassScriptPhysician profile
Iyad A Jundi
NPI 1518055144
$2,051.64
in general payments reported to CMS, 2019-2025
27 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $125 · 2021: $82.67 · 2022: $343 · 2023: $194 · 2024: $471 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $266.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $206.23 | 2022-2025 | |
| Lilly USA, LLC | $144.73 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $111.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $104.47 | 2019-2020 | |
| Pfizer INC. | $88.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.14 | 2022-2025 | Eliquis, Camzyos |
| Philips North America LLC | $87.60 | 2024 | (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.41 | 2019-2024 | Ofev |
| Janssen Pharmaceuticals, INC | $81.85 | 2024 | Opsumit |
| Glaxosmithkline, LLC. | $57.74 | 2019-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $50.52 | 2024-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $48.13 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $47.61 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.88 | 2021-2022 | |
| Amgen INC. | $39.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.44 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Harmony Biosciences LLC | $21.77 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.33 | 2022 | |
| Biogen, INC. | $18.58 | 2023 | Skyclarys |
| Acadia Pharmaceuticals INC | $17.27 | 2019 | |
| Abbott Laboratories | $15.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.48 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2022 | |
| Dexcom, INC. | $12.98 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iyad Jundi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.